Criteria Used to Determine Platinum Eligibility in Patients with Metastatic Urothelial Carcinoma: Results of a Physician Survey in Five European Countries
A survey of doctors from five European countries (France, Germany, Italy, Spain, and the UK) found that most people with metastatic urothelial cancer (77%) should be able to receive platinum-based chemotherapy. The characteristics considered by European doctors to decide whether a person can receive platinum-based chemotherapy were similar to those reported previously by US doctors, except for age. Specifically, most European doctors (67%) reported that they may be reluctant to prescribe platinum-based chemotherapy to a >80-yr-old person with metastatic urothelial cancer, whereas US doctors reported that they did not consider age in their decision.
Authors
- Nuno Marques da Costa (ORCID: https://orcid.org/0000-0003-4859-9668)
- Patrick M. Sullivan (ORCID: https://orcid.org/0000-0001-8402-2634)
- Shilpa Gupta (ORCID: https://orcid.org/0000-0002-8775-503X)
- Enrique Grande (ORCID: https://orcid.org/0000-0002-0134-4732)
- Murtuza Bharmal (ORCID: https://orcid.org/0000-0001-7689-5769)
- Silke Guenther
- Melissa Kirker
- Mairead Kearney
- Laura Panattoni (ORCID: https://orcid.org/0000-0002-5081-5043)
- Thomas B. Powles (ORCID: https://orcid.org/0000-0001-7760-4724)
- Natalie Land (ORCID: https://orcid.org/0009-0001-7928-5111)
- Thomas J. Flottemesch
Institutions
- St Bartholomew's Hospital (GB)
- Cleveland Clinic (US)
- Merck KGaA, Darmstadt (Germany) (DE)
- Queen Mary University of London (GB)
- Pfizer (United States) (US)
- MD Anderson Cancer Center Madrid (ES)
- Merck Serono S.p.A. (Italy) (IT)
Publication Details
- Journal
- European Urology Open Science
- Published
- 2025-09-24
- DOI
- https://doi.org/10.1016/j.euros.2025.08.009
- Citations
- 2
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 4.01